McCormick D, Gurwitz J H, Savageau J, Yarzebski J, Gore J M, Goldberg R J
Section for Health Services Research, Division of General Medicine/Primary Care/Geriatrics, University of Massachusetts Medical School, Worcester 01655, USA.
J Gen Intern Med. 1999 Feb;14(2):73-81. doi: 10.1046/j.1525-1497.1999.00290.x.
To assess the impact of fee-for-service (FFS) versus HMO medical insurance coverage on receipt of aspirin, beta-blockers, and calcium channel blockers at the time of hospital discharge following an acute myocardial infarction.
Prospective, population-based study.
All 16 community and tertiary care hospitals in the metropolitan area of Worcester, Massachusetts.
The study population consisted of patients under 65 years of age hospitalized with a validated acute myocardial infarction in all hospitals in the Worcester (Massachusetts) Standard Metropolitan Statistical Area (1990 census estimate, 437,000) during 1986, 1988, 1990, 1991, and 1993.
After adjustment for demographic and clinical variables as well as study year, the odds ratios for receipt of each medication for patients with HMO insurance compared with FFS were 1.05 (95% confidence interval [CI] 0.77, 1.44) for aspirin, 1.32 (95% CI 0.98, 1.76) for beta-blockers, and 0.72 (95% CI 0.54, 0.96) for calcium channel blockers. Examination of temporal trends in utilization of these agents suggests that observed decreases in use of calcium channel blockers and increases in use of beta-blockers over the period under study occurred more rapidly for HMO than for FFS patients.
Overall, use of aspirin and beta-blockers was comparable among HMO and FFS patients and use of calcium channel blockers (deemed less effective or ineffective for secondary prevention) was lower among HMO patients. Differential adoption, over time, of evidence-based prescribing practices for medications between HMO and FFS patients who have had a myocardial infarction warrants further study.
评估按服务收费(FFS)与健康维护组织(HMO)医疗保险覆盖范围对急性心肌梗死后出院时阿司匹林、β受体阻滞剂和钙通道阻滞剂使用情况的影响。
前瞻性、基于人群的研究。
马萨诸塞州伍斯特市都会区的所有16家社区和三级护理医院。
研究人群包括1986年、1988年、1990年、1991年和1993年在马萨诸塞州伍斯特市标准都市统计区(1990年人口普查估计为437,000)所有医院住院治疗且确诊为急性心肌梗死的65岁以下患者。
在对人口统计学和临床变量以及研究年份进行调整后,与FFS保险患者相比,HMO保险患者使用每种药物的比值比分别为:阿司匹林为1.05(95%置信区间[CI]0.77,1.44),β受体阻滞剂为1.32(95%CI 0.98,1.76),钙通道阻滞剂为0.72(95%CI 0.54,0.96)。对这些药物使用时间趋势的研究表明,在研究期间观察到的钙通道阻滞剂使用减少和β受体阻滞剂使用增加在HMO患者中比FFS患者发生得更快。
总体而言,HMO和FFS患者中阿司匹林和β受体阻滞剂的使用情况相当,而HMO患者中钙通道阻滞剂(被认为对二级预防效果较差或无效)的使用较少。心肌梗死患者中,HMO和FFS患者随时间对循证用药实践的不同采用情况值得进一步研究。